WEST LAFAYETTE, Ind., Jan. 24, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today provided an update regarding the review of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on the pending EU conditional marketing authorization applications for vintafolide, etarfolatide and intravenous (IV) folic acid.
Help employers find you! Check out all the jobs and post your resume.
